Bioequivalence of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a in healthy adults: Phase I, randomized, double-blind, single-dose, part

This Phase I, randomized, double-blind, single-dose, three-way crossover trial evaluated the bioequivalence of systemic and lung exposure to budesonide/glycopyrrolate/formoterol fumarate delivered via pMDIs using hydrofluoralkane-134a versus hydrofluoralkane-1234ze propellants in 108 healthy adult subjects. As part of the study, participants underwent training on inhalation technique using the Vitalograph AIM device.